Exploration of the association between SF3B4 and HMGB1 expression and the clinicopathological features and prognosis of gastric cancer

Table 4 Comparison of high mobility group box 1 expression in tissues with different clinical data, n (%)

Item	Cases, n = 114	HMGB1 expression	t	P value
Gender			0.728	0.467
Male	71 (62.28)	0.86 ± 0.13
Female	43 (37.72)	0.88 ± 0.16
Age, years			1.557	0.122
≥ 60	47 (41.23)	0.85 ± 0.11
< 60	67 (58.77)	0.89 ± 0.15
Helicobacter pylori infection			0.503	0.615
Yes	101 (88.60)	0.85 ± 0.13
No	13 (11.40)	0.87 ± 0.17
Tumor location			0.955	0.342
Fundus	38 (33.33)	0.86 ± 0.13
Body	43 (37.72)	0.89 ± 0.15
Antrum	33 (28.95)	0.87 ± 0.15
CEA			1.080	0.282
Elevated	63 (55.26)	0.88 ± 0.16
Normal	51 (44.74)	0.85 ± 0.13
Pathological type			0.621	0.535
Adenocarcinoma	102 (89.47)	0.89 ± 0.16
Others	12 (10.53)	0.86 ± 0.14
Tumor differentiation			10.158	< 0.001
Moderate-high	68 (59.65)	0.73 ± 0.08
Poor	46 (40.35)	0.95 ± 0.15
Maximum tumor diameter (cm)			10.028	< 0.001
< 5	71 (62.28)	0.69 ± 0.12
≥ 5	43 (37.72)	0.93 ± 0.13
Tumor invasion depth			9.681	< 0.001
T1-T2	35 (30.70)	0.68 ± 0.09
T3-T4	79 (69.30)	0.96 ± 0.16
Lymph node metastasis			17.636	< 0.001
Yes	84 (73.68)	0.63 ± 0.07
No	30 (26.32)	0.98 ± 0.14
cTNM stage			15.391	< 0.001
Stage I-II	34 (29.82)	0.60 ± 0.06
Stage III-IV	80 (70.18)	1.01 ± 0.15

HMGB1: High mobility group box 1; CEA: Carcinoembryonic antigen; cTNM: Clinical tumor-node-metastasis.